LAM-X: the newest spin-off company accelerated by i&i Prague in Czech Media
24.2.2020Founding of LAM-X, a.s., the newest company accelerated by i&i Prague and Charles University Innovations Prague, s.r.o. was met with both interest and positive feedback from Czech national media.
Elphogene – liquid biopsy assay for non-invasive monitoring of patients with colorectal cancer.
23.2.2020Another one of successful projects supported by i&i Prague is the Prague-based biotechnological start-up Elphogene, Inc. Its oncoMonitor™, a liquid biopsy technology, was recently turned into…
LAM-X: revolutionary wound-treating nanomaterials
21.2.2020Congratuations to LAM-X, a.s. – the newest company launched by i&i Prague! Story of LAM-X technology is a perfect example of our work in i&i…
Elphogene Technology in World Journal of Gastroenterology!
7.1.2020Another great achievement for one of our projects! Prague-based biotechnological start-up Elphogene is a progressive, young company focused on monitoring of patients in advanced stages colorectal cancer. With an…
i&i Prague became a shareholder in XENO Cell Innovations!
26.12.2019XENO Cell Innovations is a young, progressing company based in Pilsen, Czech Republic. It is focused mostly on bio-computing – capturing complex biological system in images, combining creative microscopy with…
12th BioVaria Start-up Award goes to Czech project!
12.7.2019May 2019, Munich, Germany -12th BioVaria annual Tech-Transfer conference welcomed over 250 life-science innovators to Munich, including biopharma executives, investors, academic inventors, entrepreneurs and technology transfer experts. Once again BioVaria…
Startup Riocath is among Hello Tomorrow’s top 500 stratups in the world
1.2.2019i&i Prague is excited to announce one of its partners, Riocath, will be featured among the top 500 deep tech startups at Hello Tomorrow’s upcoming global summit!
A novel method for early cancer diagnostics has been developed at University of Pardubice, and partnered with i&i Prague incubator.
10.1.2019The new diagnostic method for Pancreatic cancer has been developed by the team of prof. Holčapek, University of Pardubice. To to make it available for patients , the university has now joined forces with the Czech biotech incubator i & i Prague. The strategic collaboration should help the project to bring the diagnostic technology to a market within a few years.
Novel partnership for iBodies has been facilitated by i&i Prague and IOCB Tech managers
20.10.2018The Institute of Macromolecular Chemistry (IMC) in cooperation with the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague) started novel collaborative project with the International Cannabis and Cannabinoids Institute (ICCI). The project deals with a development of a novel synthetic antibody mimetics called iBodies® for clinical diagnostic.